University Hospital in New Jersey Purchases MicroThermX® Microwave Ablation System from BSD Medical

Before you go, we thought you'd like these...
Before you go close icon

University Hospital in New Jersey Purchases MicroThermX®Microwave Ablation System from BSD Medical

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NAS: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has sold a MicroThermX® Microwave Ablation System (MicroThermX®) to University Hospital (UH) in New Jersey. UH is the primary teaching hospital for New Jersey Medical School and other Newark-based healthcare programs and thus is uniquely positioned to help advance extraordinary scientific discoveries. UH is a model venue for the integration of education and research to promote breakthrough discoveries in healthcare. University Hospital is broadly recognized among the nation's best hospitals. Approximately one-third of the patients at University Hospital come from outside Essex County and the U.S., reflecting the breadth of services and expertise available at UH.

"We are excited to have state-of-the-art ablation treatment with the MicroThermX® available in this high-profile, prestigious hospital," stated Sam Maravich, BSD's Vice President of Sales and Marketing. "UH is a referral center for patients throughout the Northeast."


About the MicroThermX®Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermXis the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermXutilizes proprietary synchronous phased array technology that was developed and patented by BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes advanced, high-end disposables (SynchroWave antennas) that are used in each diseased soft tissue (tumor) ablation treatment, which provides a significant ongoing revenue stream. The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermXin Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermXto a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD's microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company's products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the expected use of proceeds relating to the recently completed offering. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company's products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company's most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.



BSD Medical Corporation
William Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930

KEYWORDS:   United States  North America  New Jersey  Utah

INDUSTRY KEYWORDS:

The article University Hospital in New Jersey Purchases MicroThermX® Microwave Ablation System from BSD Medical originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners